Malottki, K and Popat, S and Deeks, JJ and Riley, RD and Nicholson, AG and Billingham, L (2015) Problems of variable biomarker evaluation in stratified medicine research--A case study of ERCC1 in non-small-cell lung cancer. Lung Cancer, 92. 1 - 7. ISSN 0169-5002

Full text not available from this repository.

Abstract

OBJECTIVES: Consistency of procedures for the evaluation of a predictive biomarker (including sample collection, processing, assay and scoring system) based on adequate evidence is necessary to implement research findings in clinical practice. As a case study we evaluated how a particular predictive biomarker, ERCC1, was assessed in research on platinum-based chemotherapy in non-small-cell lung cancer and what motivated the choice of procedure. MATERIALS AND METHODS: A systematic review of studies completed since 2007 and ongoing was undertaken. Questionnaires on details of ERCC1 evaluation procedures and the rationale for their choice were sent to contacts of identified studies. RESULTS: Thirty-three studies of platinum-based chemotherapy in non-small-cell lung cancer using ERCC1 were identified. A reply to the questionnaire was received for 16 studies. Procedures for ERCC1 evaluation varied substantially and included reverse transcriptase quantitative polymerase chain reaction (nine studies), immunohistochemistry (five studies) and other methods (multiple methods-two studies, NER polymorphism-one study). In five studies ERCC1 use was planned, but not undertaken. In nine data was insufficient to identify the procedure. For each assay there was variation across studies in the details of the laboratory techniques, scoring systems and methods for obtaining samples. CONCLUSIONS: We found large variation across studies in ERCC1 evaluation procedures. This will limit the future comparability of results between these different studies. To enable evidence-based clinical practice, consensus is needed on a validated procedure to assess a predictive biomarker in the early phase of research. We believe that ERCC1 is not untypical of biomarkers being investigated for stratified medicine.

Item Type: Article
Uncontrolled Keywords: ERCC1 protein; human; biological markers; drug therapy; antieoplastic therapy; carcinoma; non-small-cell lung; clinical trials as topic
Subjects: ?? Antineoplastic therapy ??
?? Biological markers ??
?? Carcinoma ??
?? Clinical trials as topic ??
?? Drug therapy ??
?? ERCC1 protein ??
?? Human ??
?? Non-small-cell lung ??
R Medicine > R Medicine (General)
Divisions: Faculty of Medicine and Health Sciences > Primary Care Health Sciences
Related URLs:
Depositing User: Symplectic
Date Deposited: 26 May 2016 08:44
Last Modified: 26 May 2016 08:44
URI: http://eprints.keele.ac.uk/id/eprint/1782

Actions (login required)

View Item View Item